Massive Transfusion Protocol

A massive transfusion protocol (MTP) is a pre-defined institutional process for rapidly delivering large volumes of blood products in a fixed, balanced ratio to patients with life-threatening haemorrhage. It is a core component of damage control resuscitation, designed to replace not only red cells but also plasma and platelets so that clotting capacity is restored alongside oxygen-carrying capacity.

Definition

A massive transfusion protocol is a standardised, rapidly activated process for supplying packed red blood cells, plasma, and platelets in a balanced ratio (commonly approaching 1:1:1) to patients with massive or life-threatening haemorrhage, with the aim of preventing and correcting trauma-induced coagulopathy.

Scope

This entry covers the rationale for balanced blood-product ratios, the concept of an activated protocol that streamlines delivery, and the evidence linking transfusion strategy to outcome. It treats the MTP as a methodological and systems topic and the supporting trials as reference evidence, not as dosing or treatment instructions.

Core questions

• Why are plasma and platelets transfused alongside red cells in massive haemorrhage?
• What does the evidence say about balanced (1:1:1) versus more red-cell-weighted ratios?
• What is the purpose of pre-defining and activating a protocol rather than improvising?
• How does antifibrinolytic therapy relate to massive transfusion?

Key concepts

• Damage control resuscitation
• Balanced (1:1:1) blood-product ratio
• Trauma-induced coagulopathy
• Protocol activation
• Hemostatic resuscitation
• Antifibrinolytic therapy (tranexamic acid)

Mechanisms

Severe haemorrhage depletes red cells, clotting factors, and platelets simultaneously, and resuscitation with red cells or crystalloid alone can dilute remaining clotting capacity and worsen coagulopathy. A massive transfusion protocol addresses this by delivering plasma and platelets together with red cells in a balanced ratio, restoring haemostatic function as volume is replaced. Observational combat-casualty data first suggested that higher plasma-to-red-cell ratios were associated with lower mortality (Borgman, 2007), and the randomised PROPPR trial compared a 1:1:1 with a 1:1:2 ratio (Holcomb, 2015). Tranexamic acid, an antifibrinolytic, reduces bleeding-related death when given early (Shakur, 2010), and European trauma guidelines integrate these elements into bleeding management (Rossaint, 2023).

Clinical relevance

Understanding massive transfusion protocols helps in interpreting how systems are organised to manage catastrophic bleeding and the trials that inform transfusion strategy. This entry is a reference and educational description of the concept and its evidence; it is not a protocol, and it provides no dosing or individualised treatment guidance.

Epidemiology

Massive haemorrhage requiring large-volume transfusion is a relatively uncommon but high-mortality event in major trauma, and it is also encountered in obstetric, surgical, and gastrointestinal bleeding. Because trauma-induced coagulopathy is present in a substantial fraction of severely injured patients on arrival, balanced transfusion and early antifibrinolysis are emphasised in contemporary guidelines (Rossaint, 2023).

History

Civilian transfusion practice historically favoured red cells with later, reactive correction of coagulopathy. Military experience in the 2000s, particularly observational data from combat support hospitals (Borgman, 2007), shifted thinking toward early balanced delivery of plasma, platelets, and red cells as part of damage control resuscitation. The PROPPR randomised trial (Holcomb, 2015) and the CRASH-2 antifibrinolytic trial (Shakur, 2010) then provided higher-level evidence, and successive European trauma guidelines consolidated these into structured bleeding-management recommendations.

Debates

What is the optimal blood-product ratio?

Observational data favoured higher plasma-to-red-cell ratios, but the randomised PROPPR trial found no significant difference in its primary mortality endpoints between 1:1:1 and 1:1:2, leaving the precise optimal ratio and its measurement a continued subject of discussion.

Seminal works

• borgman-2007
• holcomb-2015-proppr
• shakur-2010-crash2

Frequently asked questions

Why does a massive transfusion protocol give plasma and platelets, not just red cells?

Severe haemorrhage depletes clotting factors and platelets as well as red cells, and replacing red cells alone can worsen coagulopathy; balanced delivery aims to restore clotting capacity alongside oxygen-carrying capacity.

Did the PROPPR trial prove that 1:1:1 is better than 1:1:2?

PROPPR did not show a significant difference in its primary 24-hour and 30-day mortality endpoints between the two ratios, though some secondary outcomes favoured 1:1:1; it informed but did not settle the ratio debate.